• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一项皮下给予新型制剂阿柏西普（VEGF 陷阱）治疗晚期实体瘤患者的 I 期研究。

A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.

机构信息

Washington University School of Medicine, St. Louis, MO 63110, USA.

出版信息

Invest New Drugs. 2012 Oct;30(5):1958-61. doi: 10.1007/s10637-011-9753-y. Epub 2011 Oct 15.

DOI:10.1007/s10637-011-9753-y
PMID:22002018
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3432791/
Abstract

Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in patients with advanced solid tumors. Here we report our experience with the toxicity, pharmacokinetic profile and efficacy of the new 100 mg/mL subcutaneous (SC) formulation of aflibercept administered at a dose of at 4 mg/kg every 2 weeks.

摘要

靶向血管生成是一种有效的抗癌策略。阿柏西普旨在通过阻止血管内皮生长因子（VEGF）与其受体结合来隔离循环中的 VEGF。这项 I 期研究旨在评估一种新的皮下给予阿柏西普的配方在晚期实体瘤患者中的安全性、药代动力学特征和疗效。在这里，我们报告了新的 100mg/ml 皮下（SC）阿柏西普配方的毒性、药代动力学特征和疗效，该配方以 4mg/kg 的剂量每 2 周给予一次。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b812/3432791/7b2e17f3d19c/10637_2011_9753_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b812/3432791/7b2e17f3d19c/10637_2011_9753_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b812/3432791/7b2e17f3d19c/10637_2011_9753_Fig1_HTML.jpg

相似文献

1
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.一项皮下给予新型制剂阿柏西普（VEGF 陷阱）治疗晚期实体瘤患者的 I 期研究。
Invest New Drugs. 2012 Oct;30(5):1958-61. doi: 10.1007/s10637-011-9753-y. Epub 2011 Oct 15.
2
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.晚期实体瘤患者皮下给予阿柏西普的 1 期研究。
Clin Cancer Res. 2010 Jan 1;16(1):358-66. doi: 10.1158/1078-0432.CCR-09-2103. Epub 2009 Dec 22.
3
Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.晚期实体瘤患者游离型和结合型阿柏西普的群体药代动力学分析。
Cancer Chemother Pharmacol. 2013 Jul;72(1):167-80. doi: 10.1007/s00280-013-2182-1. Epub 2013 May 15.
4
Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.阿柏西普静脉注射联合多西他赛、顺铂和5-氟尿嘧啶用于晚期实体恶性肿瘤患者的I期剂量递增及药代动力学研究
Oncology. 2016;90(1):10-20. doi: 10.1159/000440958. Epub 2015 Oct 23.
5
Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies.在晚期实体恶性肿瘤的日本患者中，评估 aflibercept 联合 S-1 的安全性、耐受性和药代动力学的 I 期剂量递增研究。
Invest New Drugs. 2020 Oct;38(5):1390-1399. doi: 10.1007/s10637-019-00888-z. Epub 2020 Jan 6.
6
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.静脉血管内皮生长因子陷阱，阿柏西普，在晚期实体瘤患者中的 I 期研究。
J Clin Oncol. 2010 Jan 10;28(2):207-14. doi: 10.1200/JCO.2009.22.9237. Epub 2009 Nov 30.
7
Aflibercept: A Review in Metastatic Colorectal Cancer.阿柏西普：转移性结直肠癌的研究进展。
Drugs. 2015 Aug;75(12):1435-45. doi: 10.1007/s40265-015-0444-4.
8
A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report.在难治性实体瘤儿童中进行的阿柏西普（VEGF Trap）的 I 期试验和药代动力学研究：儿童肿瘤学组 I 期联盟报告。
Clin Cancer Res. 2012 Sep 15;18(18):5081-9. doi: 10.1158/1078-0432.CCR-12-0078. Epub 2012 Jul 12.
9
Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?阿柏西普（VEGF 陷阱）：抗 VEGF 治疗抗癌的又一双刃剑？
Clin Transl Oncol. 2010 Aug;12(8):526-32. doi: 10.1007/s12094-010-0550-4.
10
Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors.阿柏西普：一种新型 VEGFR 靶向药物，探索抗血管生成治疗多种肿瘤的未来前景。
Mini Rev Med Chem. 2013 Apr;13(4):530-40. doi: 10.2174/1389557511313040006.

引用本文的文献

1
Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome.药品说明书：阿柏西普和硫酸长春新碱脂质体。
Hosp Pharm. 2013 Jan;48(1):14-22. doi: 10.1310/hpj4801-14.
2
New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy.转移性结直肠癌二线治疗的新进展：治疗中的潜在地位。
Drugs. 2013 Jun;73(9):883-91. doi: 10.1007/s40265-013-0076-5.

本文引用的文献

1
Hallmarks of cancer: the next generation.癌症的特征：下一代。
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
2
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.一项多中心、2 期研究评估了血管内皮生长因子陷阱（阿柏西普）在铂类和厄洛替尼耐药肺腺癌中的应用。
J Thorac Oncol. 2010 Jul;5(7):1054-9. doi: 10.1097/jto.0b013e3181e2f7fb.
3
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.
晚期实体瘤患者皮下给予阿柏西普的 1 期研究。
Clin Cancer Res. 2010 Jan 1;16(1):358-66. doi: 10.1158/1078-0432.CCR-09-2103. Epub 2009 Dec 22.
4
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.静脉血管内皮生长因子陷阱，阿柏西普，在晚期实体瘤患者中的 I 期研究。
J Clin Oncol. 2010 Jan 10;28(2):207-14. doi: 10.1200/JCO.2009.22.9237. Epub 2009 Nov 30.
5
VEGF-targeted therapy: mechanisms of anti-tumour activity.血管内皮生长因子靶向治疗：抗肿瘤活性机制
Nat Rev Cancer. 2008 Aug;8(8):579-91. doi: 10.1038/nrc2403. Epub 2008 Jul 3.
6
Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.血管内皮生长因子受体阻滞剂在原位小鼠肾细胞癌模型中可阻断肿瘤生长、转移形成及血管渗漏。
Clin Cancer Res. 2007 Jul 15;13(14):4201-8. doi: 10.1158/1078-0432.CCR-06-2553.
7
VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma.血管内皮生长因子受体阻滞剂联合放射治疗可改善U87胶质母细胞瘤的肿瘤控制情况。
Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1526-37. doi: 10.1016/j.ijrobp.2006.11.011. Epub 2007 Jan 17.
8
Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.血管内皮生长因子受体阻滞剂联合紫杉醇显著抑制肿瘤和腹水，延长人卵巢癌模型的生存期。
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6966-71. doi: 10.1158/1078-0432.CCR-05-0910.
9
Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines.血管内皮生长因子陷阱抑制多种胰腺癌细胞系的致瘤性。
Clin Cancer Res. 2004 May 15;10(10):3327-32. doi: 10.1158/1078-0432.CCR-03-0820.
10
Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.血管内皮生长因子陷阱可减轻卵巢癌模型中的肿瘤负担，抑制腹水形成，并引起显著的血管重塑。
Clin Cancer Res. 2003 Nov 15;9(15):5721-8.